Skip to content
Research peptidesmelanotan

Melanotan: What the Published Cases Show

Melanotan products are unapproved tanning peptides, and the published human record is mostly case reports of serious harm. What those cases describe.

Start here

Plain English

Melanotan products are unapproved tanning peptides, and the published human record is dominated by case reports of serious harm rather than efficacy studies. This page is a safety read rather than a how-to.

  • Not approved cosmetics or medicines for tanning.
  • Published cases describe serious harms.
  • We do not treat this as a lifestyle shortcut.

Melanotan shows up in searches next to “safe tan” and “peptide nasal spray.” The medical literature’s tone is closer to case-report alarm than spa menu.

What people mean

“Melanotan” usually refers to unapproved synthetic peptides (commonly melanotan I or II) sold for tanning or related effects. They are not an FDA-approved over-the-counter tan.

Evidence of harm is not theoretical

Published case literature includes:

Those are serious events. They are the opposite of “mild side effects, totally fine.”

Evidence strength for “it works safely”

Limited human data

Small or uncontrolled human studies. Too little to settle the question either way. Case reports of serious adverse events; not a body of high-quality RCTs establishing safe consumer tanning use. Unapproved marketing is not a safety program.

How this fits the site’s model

Melanotan sits with research / unapproved products - not clean cosmetics, not approved prescription medicines with labelled risk-benefit for that use.

See also: peptide side effects · are peptides safe? · research peptides and the law

References

Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.

  1. 1.Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019;12(2).ReviewPMID 30796078full text
  2. 2.Peters B, Hadimeri H, Wahlberg R et al. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159-161.ReviewPMID 31953620full text
  3. 3.FDA - general drug approval and unapproved drug framework context; see also FDA communications on unapproved products marketed for human use.- US Food and Drug Administrationregulatory